NEW YORK (GenomeWeb) – Rennova Health announced today that it has partnered with Certainty Health to develop a smartphone-based platform to offer molecular tests enabling the precision treatment of psychiatric disorders.
Under the terms of the deal, Rennova will offer genetic tests — developed by its subsidiary Advanced Molecular Services (AMS) Group under the Certainty Health brand — directly to consumers via a mobile platform. The first tests will include ones that can help determine how an individual may respond to various drugs used to treat psychiatric disorders.
Rennova said that the general availability of the platform and online ordering of its molecular tests is expected by the fourth quarter of 2017. Additional terms were not disclosed.
"Today the cost of and access to these tests is prohibitive to the people who need it most," AMS Group CEO Scott Jenkins said in a statement. "Modern e-commerce and mobile tools will bring immediate access to these life-changing diagnostics and tools to everyone."
Rennova formed AMS Group earlier this year through a merger of three of its subsidiaries: CollabRx, a clinical decision-support company that merged with Medytox Solutions in 2015 to become Rennova; Genomas, a pharmacogenomics testing firm Rennova fully acquired last year; and Alethea Laboratories, which Medytox acquired in early 2013.